Table 1 Baseline characteristics of in situ breast cancer case and control subjects (data presented as median [min, max] or n [%])
Premenopausal women* | Postmenopausal women* | |||
|---|---|---|---|---|
Cases (n = 86) | Controls (n = 86) | Cases (n = 221) | Controls (n = 221) | |
Age at blood donation, years | 46.4 (34.1, 56.4) | 46.5 (34.4, 55.6) | 58.1 (47.7, 70.6) | 58.0 (47.7, 71.4) |
Age at menopause, years | 50.0 (33.0, 59.0) | 50.0(29.0,58.0) | ||
Age at diagnosis, years | 50.6 (37.3, 61.3) | 62.8 (51.0, 78.3) | ||
Lag time till diagnosis, years | 4.1 (0.02, 10.0) | 4.4 (0.02, 10.7) | ||
Body mass index, kg/m2 | 23.3 (17.1, 32.8) | 24.0 (17.4, 37.2) | 24.9 (17.8, 40.8) | 24.5 (18.2, 45.9) |
Ever had a full-term pregnancy | 68 (82.9) | 70 (81.4) | 190 (86.8) | 188 (85.5) |
Baseline smoking | 15 (17.4) | 20 (23.3) | 25 (11.3) | 33 (14.9) |
Baseline use of hormone therapy | 82 (37.1) | 82 (37.1) | ||
Prolactin levels, ng/mL | 8.9 (3.4, 51.7) | 7.7 (2.9, 133.0) | 6.2 (2.6, 128.3) | 5.9 (2.6, 55.3) |